Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Enterprise Value : $510.62 Mil (As of May. 13, 2024)

Keryx Biopharmaceuticals Enterprise Value Chart

Keryx Biopharmaceuticals Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
Enterprise Value		Get a 7-Day Free Trial					1,014.49	1,225.63	421.44	633.41	585.71

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Enterprise Value	Get a 7-Day Free Trial															856.90	585.71	557.55	533.26	515.45

Competitive Comparison of Keryx Biopharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Keryx Biopharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keryx Biopharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's Enterprise Value falls into.

Keryx Biopharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Keryx Biopharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2017 is calculated as

Keryx Biopharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keryx Biopharmaceuticals  (NAS:KERX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Keryx Biopharmaceuticals's EV-to-EBIT for today is

Keryx Biopharmaceuticals's current Enterprise Value is $510.62 Mil.
Keryx Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.79 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Keryx Biopharmaceuticals's EV-to-EBITDA for today is:

Keryx Biopharmaceuticals's current Enterprise Value is $510.62 Mil.
Keryx Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.81 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Keryx Biopharmaceuticals's EV-to-Revenue for today is:

Keryx Biopharmaceuticals's current Enterprise Value is $510.62 Mil.
Keryx Biopharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $94.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keryx Biopharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description